Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €94.00 EUR
Change Today -1.01 / -1.07%
Volume 0.0
As of 3:17 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

zimmer biomet holdings inc (ZIM) Snapshot

Open
€94.00
Previous Close
€95.01
Day High
€94.00
Day Low
€94.00
52 Week High
03/13/15 - €112.19
52 Week Low
08/8/14 - €70.60
Market Cap
19.1B
Average Volume 10 Days
4.4
EPS TTM
--
Shares Outstanding
203.3M
EX-Date
05/13/15
P/E TM
--
Dividend
€0.85
Dividend Yield
0.79%
Current Stock Chart for ZIMMER BIOMET HOLDINGS INC (ZIM)

zimmer biomet holdings inc (ZIM) Related Businessweek News

No Related Businessweek News Found

zimmer biomet holdings inc (ZIM) Details

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. It offers orthopaedic reconstructive devices that restore function lost due to disease or trauma in joints comprising knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons for the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. The company also provides related surgical products, such as surgical supplies and instruments to aid in orthopedic surgical procedures and post-operation rehabilitation; and other healthcare related services. It primarily serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, and healthcare dealers, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

10,000 Employees
Last Reported Date: 02/23/15
Founded in 1927

zimmer biomet holdings inc (ZIM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $934.9K
President of Europe, Middle East and Africa
Total Annual Compensation: $597.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $426.0K
Advisor
Total Annual Compensation: $556.1K
Advisor
Total Annual Compensation: $539.9K
Compensation as of Fiscal Year 2014.

zimmer biomet holdings inc (ZIM) Key Developments

Zimmer Biomet Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year 2015; Provides Earnings Guidance for the Third Quarter and Second Half of 2015

Zimmer Biomet Holdings, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $1,167.6 million against $1,182.9 million a year ago. Operating loss was $129.5 million against operating profit of $260.9 million a year ago. Loss before income taxes was $213.7 million against income before income taxes of $236.4 million a year ago. Net loss of the company was $158.0 million against net income of $176.5 million a year ago. Diluted loss per share was $0.91 against diluted earnings per share of $1.03 a year ago. The loss is due principally to expenses incurred during the quarter in connection with the Biomet merger. Adjusted net earnings were $278.7 million against $271.0 million a year ago. Adjusted diluted earnings per share were $1.59 against $1.58 a year ago. Operating cash flow for the second quarter was $186.8 million. Net currency impact for the quarter decreased revenues by 7% or $83 million. Adjusted operating profit amounted to $395.3 million. Free cash flow was $114.8 million, $44.7 million lower than the second quarter of 2014. Capital expenditures for the quarter totaled $72 million, including $41.6 million for instruments and $30.4 million for property, plant and equipment. For the six months, the company reported net sales of $2,302.0 million against $2,344.4 million a year ago. Operating profit was $145.4 million against $561.0 million a year ago. Earnings before income taxes were $181.1 million against $522.3 million a year ago. Net earnings of the company were $19.1 million against $398.0 million a year ago. Diluted earnings per share were $0.11 against $2.32 a year ago. Net cash provided by operating activities was $278.3 million against $442.9 million a year ago. Additions to instruments were $104.0 million against $112.0 million a year ago. Additions to other property, plant and equipment was $64.8 million against $63.4 million a year ago. Adjusted net earnings were $551.5 million against $545.5 million a year ago. Adjusted diluted earnings per share were $3.17 against $3.18 a year ago. The company updated its full-year 2015 reported sales and adjusted earnings per share guidance, and reaffirmed constant currency sales growth for 2015 for the combined entity. Full-year 2015 constant currency revenue, compared to pro forma 2014 revenue, is still expected to increase between 1.5% and 2.0%. The pro forma adjustments to the prior year reflect the inclusion of Biomet revenue for the comparable post-merger closing period in the prior year and the impact of the previously announced divestiture remedies. The company expects foreign currency translation to decrease revenues approximately 6.0% for the full year, resulting in reported revenue decreasing between 4.0% and 4.5% when compared to pro forma 2014 revenue. The company now expects full-year 2015 diluted earnings per share to be in a range of $6.65 to $6.80 on an adjusted basis. Previously, the company estimated fully diluted adjusted earnings per share to be in a range of $6.60 to $6.80. The company also continues to project $350 million in pre-tax, net synergies by the end of the third year following the merger closing. Additionally, within the first twelve months post-closing, the company continues to expect to realize earnings per share accretion in a range of $0.95 to $1.05 relating to the Biomet merger, with $135 million of pre-tax, net synergy savings. For the second half of 2015, the company expects constant currency pro forma revenue growth on a day rate basis to be between 1% and 2%. The company expects gross margin to be in a range of 75% to 75.5%. The adjusted effective tax rate is estimated to be between 26.5% and 27%. The fully diluted share count for the second half is approximately 206.5 million shares. Adjusted diluted earnings per share would be in a range of $3.45 and $3.60. For the third quarter, the company expects adjusted diluted earnings per share to be in a range of $1.52 and $1.57.

Zimmer Holdings, Inc. Announces Management Changes

On June 24, 2015, Zimmer Holdings, Inc. completed its previously announced acquisition of Biomet, Inc. In connection with the closing of the Merger, James T. Crines, the company's Executive Vice President, Finance and Chief Financial Officer, stepped down from that position effective as of June 24, 2015. Mr. Crines will continue to be employed by the company until his retirement on August 3, 2015, following 20 years of service to the company. Also as previously announced, in connection with the closing of the Merger, Stephen H.L. Ooi, the company's President, Asia Pacific, stepped down from that position effective as of June 24, 2015. Mr. Ooi will continue to be employed by the company until his retirement on December 31, 2015, following 29 years of service to the company. In addition, in connection with the closing of the Merger, Derek M. Davis, the company's Vice President, Finance and Corporate Controller and Chief Accounting Officer was appointed Vice President, Global Integration of the company and will no longer serve in the role of principal accounting officer of the company, effective as of June 24, 2015. Effective upon the closing of the Merger, the company's board of directors appointed the following new executive officers: Daniel P. Florin, age 51, was appointed Senior Vice President and Chief Financial Officer of the company, succeeding Mr. Crines. Mr. Florin served as Senior Vice President and Chief Financial Officer of Biomet from June 2007 until the closing of the Merger. Prior to joining Biomet, Mr. Florin served as Vice President and Corporate Controller of Boston Scientific Corporation from 2001 until 2007. Tony W. Collins, age 46, was appointed Vice President, Corporate Controller and Chief Accounting Officer of the company, succeeding Mr. Davis. In connection with this appointment, Mr. Collins was designated as the company's principal accounting officer. Previously, Mr. Collins served as Vice President, Finance for Zimmer's Global Reconstructive Division and Global Operations organization.

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Second Quarter of 2015; Revises Earnings Guidance for the Full Year 2015

Zimmer Biomet Holdings, Inc. provided earnings guidance for the second quarter of 2015. The company estimates second quarter 2015 constant currency revenue growth, excluding Biomet acquired revenue, to be in a range of 1.0% to 1.5%, or 1.5% to 2.0% on a billing day, constant currency basis. The company estimates second quarter 2015 adjusted, fully diluted earnings per share to be in a range of $1.55 to $1.58. The company revised its earnings guidance for the full year of 2015. For the full year 2015, constant currency revenue compared to pro forma 2014 revenues is now expected to increase between 1.5% and 2.0%. Previously, the company had estimated full-year constant currency revenue would increase between 1.5% and 2.5% over 2014 pro forma revenues. The company estimates fully diluted earnings per share to be in a range of $6.60 to $6.80.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIM:GR €94.00 EUR -1.01

ZIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.11 USD -0.23
Cerner Corp $70.90 USD -0.82
Endo International PLC $86.99 USD -0.55
Intuitive Surgical Inc $526.50 USD -6.67
St Jude Medical Inc $73.40 USD -0.42
View Industry Companies
 

Industry Analysis

ZIM

Industry Average

Valuation ZIM Industry Range
Price/Earnings 52.8x
Price/Sales 3.9x
Price/Book 1.8x
Price/Cash Flow 61.6x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIMMER BIOMET HOLDINGS INC, please visit www.zimmer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.